Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects

David J. Hinton1,2,3, Marely Santiago Vázquez4, Jennifer R. Geske5, Mario J. Hitschfeld6, Ada M. C. Ho2, Victor M. Karpyak1, Joanna M. Biernacka1,5 & Doo-Sup Choi1,2,3

Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.

Alcohol use disorder (AUD) is a heterogeneous and complex psychiatric disorder that affects 4–5% of the world population. It is often associated with other substance disorders as well as other psychiatric disorders and represents a substantial worldwide economic burden. The heterogeneity of patient populations with AUD as well as associated comorbidities complicate treatment outcome. This is underscored by the fact that the number needed to treat (NNT) to prevent one person from returning to any alcohol consumption for acamprosate is 12 and for naltrexone is 20 while studies of disulfiram do not support an association with preventing return to heavy drinking. This heterogeneity in AUD suggests that a single drug will not work for all patients. Although research should focus on the development of novel medications for the treatment of AUD, perhaps the best way to optimize the currently available FDA approved medications (disulfiram, naltrexone and acamprosate) as well as any new drugs that are approved in the future, is to identify biomarkers of treatment response in an effort to develop a personalized medicine approach in AUD.

The goal of personalized medicine is to identify a single or group of measurable biological factors that are capable of identifying which patients have the highest likelihood of responding to a particular treatment intervention. Personalized medicine in alcohol use disorder is still at its early stages but has first focused on pharmacogenomics biomarkers of treatment response. A single nucleotide polymorphism (SNP) in the μ-opioid receptor gene (OPRM1) was found to be associated with naltrexone treatment response. However, when a prospective study was conducted to determine whether this particular SNP in OPRM1 predicts naltrexone response...
response, the authors were unable to conclude that the Asp40 allele of OPRM1 moderates response to naltrexone treatment. More traction has been gained when examining pharmacogenomics makers of acamprosate treatment response. Several independent groups have found associations between SNPs in a GABAA receptor subunit gene [GABRB2], a transcription factor for atrial natriuretic peptide [GATA4] and an NMDA glutamate receptor subunit gene [GRIN2B] with acamprosate treatment response. In addition, in animal studies, mice that lack type 1 equilibrative nucleoside transporter [ENT1] or have a mutation in period 2 [PER2] showed reduced alcohol consumption in response to acamprosate treatment while no effect was observed in wild-type mice. However, prospective studies to evaluate the predictive power of these pharmacogenomics biomarkers have not been performed.

Metabolomics can identify pretreatment or response-to-treatment metabolotypes that can be associated with the outcome of a particular pharmacological intervention. Thus, metabolic signatures that are associated with a positive or negative treatment response could be used to predict patient treatment outcomes. Several studies have used metabolomics to identify baseline pre-treatment metabolic signatures that are associated with treatment response to sertraline in depression and to antipsychotics in schizophrenia. In addition, we have used a metabolomics method to identify baseline metabolites that are associated with treatment response to acamprosate in patients with AUD.

In this study, we aimed to investigate the potential utility of multivariable models incorporating baseline metabolic and clinical biomarkers to identify patients that have the highest likelihood of a positive treatment response (no alcohol consumption for at least 3 months) to acamprosate. Overall, the identification of biomarkers and the development of predictive models that are capable of predicting therapeutic response to pharmacological agents for treatment of AUD could help physicians to determine which medication to prescribe for individual AUD patients, enabling personalized medicine in AUD. To our knowledge, this is the first study describing the use of predictive models incorporating both metabolomic and clinical biomarkers to determine treatment response to acamprosate.

Results
Differences in baseline demographics, alcohol use history and clinical features between responders and non-responders. Prior to building multivariable predictive models of acamprosate response, we compared baseline demographic and clinical features between responders and non-responders. There was no difference in age at time of consent or race between responders and non-responders; however, there was a higher proportion of males in the responder group (P=0.029). There was no difference in the number of days sober in the past 3 months before entering the study or the average number of drinks per drinking day during the 3 months prior to entering the study compared to non-responders (P=0.059). The baseline activity of glutamine synthetase and baseline GGT levels were similar between the groups (Table 1).

Differences in baseline serum metabolites between responders and non-responders. We evaluated the level of 36 serum amino acids and amino acid derivatives in responders and non-responders to 3 months of acamprosate treatment (Table 2). We found that levels of 6 metabolites (glutamate, ammonia, 1-methylhistidine, taurine, aspartate, and threonine) were different between responders and non-responders (uncorrected P<0.05).

Predictive model development using the training samples and evaluation of performance in the test samples. Table 3 shows the best model, based on five-fold cross-validation, for prediction of acamprosate treatment response in each of the 5 random training subsets. PACS score and aspartate were the most

| Measure              | Responders (n=71) | Non-responders (n=49) | P Value |
|----------------------|-------------------|-----------------------|---------|
| **Demographics**     |                   |                       |         |
| Age at consent       | 45.9±9.4          | 44.7±11.6             | 0.549   |
| Gender (male)        | 54±76.1           | 28±57.1               | 0.029   |
| Race (Caucasian)     | 67±94.4           | 43±87.8               | 0.198   |
| No. of drinks/day (3 months prior) | 11.9±9.9 | 9.0±4.7               | 0.059   |
| No. of drinks/day (1 month prior) | 10.4±12.7 | 7.5±5.5               | 0.137   |
| No. of days since last drink | 27.7±24.2 | 20.9±19.7             | 0.157   |
| **Clinical Characteristics** |             |                       |         |
| Baseline PACS Score  | 11.6±7.1          | 16.4±8.6              | <0.001  |
| GS activity          | 4.3±2.7           | 3.8±1.9               | 0.660   |
| GGT                  | 82.1±88.1         | 62.0±70.4             | 0.737   |

Table 1. Comparison of demographics, drinking history, and clinical characteristics between responders and non-responders. GS: glutamine synthetase; GGT: glutamyl transpeptidase; PACS: Pennsylvania Alcohol Craving Scale; SD: Standard Deviation.
consistently selected predictors, being included in all five predictive models. 1-Methylhistidine, ammonia, taurine, threonine, and male gender were all included in at least two predictive models. Table 4 presents the performance of the models in the five testing samples. The area under the ROC curve (AUC) in the test set varied between the five random data splits, ranging from 0.570 to 0.724 (mean 0.647) (Fig. 1). In the test samples, the models predicted acamprosate treatment response with a sensitivity ranging from 0.708 to 1.000 (mean sensitivity $= 0.833$) and a specificity ranging from 0.059 to 0.500 (mean specificity $= 0.310$).

**Discussion**

This study investigated the possibility of establishing a model to predict acamprosate treatment response in alcohol dependent patients utilizing demographics, alcohol use history, clinical assessments and serum metabolite levels. Overall, our findings suggest that combining baseline serum metabolites and clinical scores as variables in a multivariate model provides some predictive power to differentiate responders and non-responders to 3 months of acamprosate treatment. However, the mean AUC of 0.65 and the poor specificity of the predictive models, suggests that studies with larger sample sizes that explore more potential biomarkers are needed to expand the clinical utility of predictive algorithms for pharmaceutical response in AUD. To our knowledge, this is the first study that evaluates the potential accuracy of predictive models that incorporate metabolomic biomarkers and clinical factors to determine treatment response to acamprosate. This approach could potentially be used to predict response to other FDA-approved medications as well as novel drugs to treat AUD.

| Measure | Responders (n = 71) | Non-responders (n = 49) | P Value |
|---------|---------------------|------------------------|---------|
| Serum Metabolite Levels | Mean or n | SD or % | Mean or n | SD or % | |
| 1-Methylhistidine | 7.50 | 5.87 | 13.14 | 17.19 | 0.023 |
| 3-Methylhistidine | 4.36 | 2.92 | 4.47 | 2.20 | 0.822 |
| α-aminoadipic acid | 1.10 | 0.68 | 0.83 | 0.60 | 0.027 |
| α-aminon-butyric | 13.63 | 5.33 | 15.57 | 7.03 | 0.089 |
| Alanine | 400.38 | 79.59 | 389.94 | 92.85 | 0.511 |
| Ammonia | 34.40 | 17.66 | 26.17 | 13.22 | 0.007 |
| Arginine | 100.39 | 23.52 | 98.41 | 24.69 | 0.659 |
| Asparagine | 61.20 | 14.97 | 61.86 | 17.51 | 0.825 |
| Aspartate | 19.00 | 10.14 | 13.00 | 6.90 | $< 0.001$ |
| β-alanine | 5.47 | 2.05 | 5.18 | 0.91 | 0.225 |
| Table 2. Baseline serum metabolite levels in responders and non-responders to 3-month acamprosate treatment in the training sample. SD: Standard Deviation. | | | | | |
was associated with elevated baseline glutamate levels. In addition, several studies have identified genetic asso-
ciation with alcohol craving, it suggests that a patient with lower craving that has been abstinent from 1
week or less may be the ideal candidate for treatment. Previously, we found that acamprosate treatment response
in patients with shorter abstinence length before initiation of treatment. Although this is not a
hol may be more likely to be treated with acamprosate or abstain in general from alcohol consumption. On the
other hand, data from the COMBINE study was reanalyzed and it was found that acamprosate was most effective
in patients with shorter abstinence. These data suggest that patients with low craving for alcohol may be more likely to respond but eventually do not respond to acamprosate treatment – in order to correctly identify most patients that are likely to respond to this treatment. Nevertheless, to be clinically useful a predictive model should have high sensitivity and at least moderately high specificity. The low specificity in our study may partly reflect
over-fitting and is also due to the difference in responder/non-responder proportions (i.e. data imbalance). In our
random split of the sample into training and test data (which was done 5 independent times), we performed a
stratified random split, so that the ratio of responders to non-responders would be similar in all the training and
test subsets. Because in the complete sample the number of responders is higher than non-responders (59% vs. 41%), each training and test set also had this unbalanced number of cases and controls.

Our models had an average area under a receive operating characteristic (ROC) curve of 0.80 in the training
samples and an AUC of 0.65 in the test samples. Prospective studies using a larger sample are necessary to identify new models with improved predictive power. A novel aspect of our model is the inclusion of serum metabolites as predictors. Using metabolomics to aid in prescription of medications is feasible since metabolomics can be ordered as a clinical test used to evaluate a patient’s pretreatment metabolite signature prior to selection of a pharmacological agent, but standardization of the method between laboratories is critical.

We found that baseline PACS and aspartate levels were the two variables that consistently were associated with acamprosate treatment response in all 5 models. Lower craving scores have been reported by our previous study to be associated with acamprosate treatment response. Furthermore, our group has also found that increased alcohol craving is associated with shorter abstinence. These data suggest that patients with low craving for alcohol may be more likely to be treated with acamprosate or abstain in general from alcohol consumption. On the other hand, data from the COMBINE study was reanalyzed and it was found that acamprosate was most effective in patients with shorter abstinence (1 week or less) length before initiation of treatment. Although this is not a direct assessment of alcohol craving, it suggests that a patient with lower craving that has been abstinent from 1 week or less may be the ideal candidate for treatment. Previously, we found that acamprosate treatment response was associated with elevated baseline glutamate levels. In addition, several studies have identified genetic associations related to glutamate signaling with acamprosate treatment response. In the present study, we found that aspartate and glutamate levels were significantly elevated in responders to acamprosate and associated with acamprosate treatment response, although aspartate was the only amino acid significantly associated with acamprosate response in all 5 predictive models. Interestingly, aspartate can be converted to glutamate via aspartate transaminase (AST) in serum. AST is frequently used as a marker of liver function and has been used as a marker of alcohol use. Future studies that incorporate metabolomic, genetic, and clinical characteristics as variables may reveal better prospective predictive models that could be used to predict acamprosate treatment response.

Our findings should be considered in light of the study’s limitations. It is important to emphasize that the metabolomic variables considered in this investigation were collected from serum, which may not directly reflect the metabolite levels in the brain. Future studies should be conducted to evaluate baseline brain metabolite level differences between responders and non-responders using non-invasive techniques such as magnetic resonance spectroscopy (MRS), and establish the relationship between blood and brain metabolites, so that using blood metabolites, which is more cost-effective, as proxy to those in the brain could be justified. On the other hand, a baseline serum metabolite profile provides a more feasible clinical test to screen for potential response type than that from an MRS scan. In addition, the clinical features and the types of metabolites we used in the development of the predictive models are vast yet limited. Further studies using global metabolomics, which covers all the detectable metabolites may lead to stronger predictive models to predict acamprosate treatment response. In addition, based on recent finding that the active component of acamprosate might be calcium, calcium-regulating metabolites may play a role in determining acamprosate treatment response. However, global

| Predictor | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|-----------|---------|---------|---------|---------|---------|
| Intercept | −0.601  | 0.558   | 0.642   | 0.252   | 0.340   |
| Baseline PACS | −0.015  | −0.061  | −0.057  | −0.005  | −0.023  |
| Aspartate | 0.026   | 0.034   | 0.030   | 0.012   | 0.014   |
| Methylhistidine | −0.006  | −0.001  | —       | −0.027  | —       |
| Ammonia   | 0.009   | —       | —       | 0.005   | —       |
| Taurine   | —       | 0.003   | —       | —       | 0.001   |
| Threonine | —       | −0.003  | —       | —       | —       |
| Phosphoethanolamine | —       | —       | —       | —       | 0.012   |
| Gender (male) | 0.554   | —       | —       | 0.182   | —       |
| Caucasian | 0.110   | —       | —       | —       | —       |

Table 3. Multivariable logistic regression model variables selected by Lasso penalized selection method.

We found that the average sensitivity was high in the training (94.9%) and the test (83.3%) samples. A high
sensitivity suggests that this model is very good at detecting true positives or those that are predicted to respond and do respond to acamprosate. From a clinical perspective, identifying those patients that are predicted to respond would allow the patient to get the best medication for them at the beginning of treatment. This could dramatically improve the ways that patients with AUD are treated. The low specificity indicates that the model is unable to identify non-responders. Caution should be noted as, if too many people are predicted to “respond” among eventual non-responders, they may be given a treatment from which they may not benefit. However, given how few pharmacological treatment options are available for AUDs, we believe that in this context high sensitivity is more important than high specificity, i.e. we are willing to accept some false positives – patients who are predicted to respond but eventually do not respond to acamprosate treatment – in order to correctly identify most patients that are likely to respond to this treatment. Nevertheless, to be clinically useful a predictive model should have high sensitivity and at least moderately high specificity. The low specificity in our study may partly reflect
over-fitting and is also due to the difference in responder/non-responder proportions (i.e. data imbalance). In our
random split of the sample into training and test data (which was done 5 independent times), we performed a
stratified random split, so that the ratio of responders to non-responders would be similar in all the training and
test subsets. Because in the complete sample the number of responders is higher than non-responders (59% vs. 41%), each training and test set also had this unbalanced number of cases and controls.

Our models had an average area under a receive operating characteristic (ROC) curve of 0.80 in the training
samples and an AUC of 0.65 in the test samples. Prospective studies using a larger sample are necessary to identify new models with improved predictive power. A novel aspect of our model is the inclusion of serum metabolites as predictors. Using metabolomics to aid in prescription of medications is feasible since metabolomics can be ordered as a clinical test used to evaluate a patient’s pretreatment metabolite signature prior to selection of a pharmacological agent, but standardization of the method between laboratories is critical.

We found that baseline PACS and aspartate levels were the two variables that consistently were associated with acamprosate treatment response in all 5 models. Lower craving scores have been reported by our previous study to be associated with acamprosate treatment response. Furthermore, our group has also found that increased alcohol craving is associated with shorter abstinence. These data suggest that patients with low craving for alcohol may be more likely to be treated with acamprosate or abstain in general from alcohol consumption. On the other hand, data from the COMBINE study was reanalyzed and it was found that acamprosate was most effective in patients with shorter abstinence (1 week or less) length before initiation of treatment. Although this is not a direct assessment of alcohol craving, it suggests that a patient with lower craving that has been abstinent from 1 week or less may be the ideal candidate for treatment. Previously, we found that acamprosate treatment response was associated with elevated baseline glutamate levels. In addition, several studies have identified genetic associations related to glutamate signaling with acamprosate treatment response. In the present study, we found that aspartate and glutamate levels were significantly elevated in responders to acamprosate and associated with acamprosate treatment response, although aspartate was the only amino acid significantly associated with acamprosate response in all 5 predictive models. Interestingly, aspartate can be converted to glutamate via aspartate transaminase (AST) in serum. AST is frequently used as a marker of liver function and has been used as a marker of alcohol use. Future studies that incorporate metabolomic, genetic, and clinical characteristics as variables may reveal better prospective predictive models that could be used to predict acamprosate treatment response.

Our findings should be considered in light of the study’s limitations. It is important to emphasize that the metabolomic variables considered in this investigation were collected from serum, which may not directly reflect the metabolite levels in the brain. Future studies should be conducted to evaluate baseline brain metabolite level differences between responders and non-responders using non-invasive techniques such as magnetic resonance spectroscopy (MRS), and establish the relationship between blood and brain metabolites, so that using blood metabolites, which is more cost-effective, as proxy to those in the brain could be justified. On the other hand, a baseline serum metabolite profile provides a more feasible clinical test to screen for potential response type than that from an MRS scan. In addition, the clinical features and the types of metabolites we used in the development of the predictive models are vast yet limited. Further studies using global metabolomics, which covers all the detectable metabolites may lead to stronger predictive models to predict acamprosate treatment response. In addition, based on recent finding that the active component of acamprosate might be calcium, calcium-regulating metabolites may play a role in determining acamprosate treatment response. However, global
metabolomics approaches are only semi-quantitative. Finally, although the quantification of metabolite concentrations using LC/MS/MS is based on standard concentration curves and each sample is spiked with an internal standard for normalization between sample runs, it is possible that concentrations of metabolites may vary between analysis batches or institutions. Thus, the use of metabolite ratios may allow consistency between analysis batches or institutions.

In conclusion, our study highlights the use of metabolic and clinical biomarkers to create a predictive model to determine whether or not any single patient with AUD has a good probability of responding to acamprosate. This study takes us one step closer to a personalized treatment approach for patients with AUD.

**Methods**

**Subjects.** The study was conducted in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the Institutional Review Board of Mayo Clinic (IRB number: 07-007204); all participants provided informed consent. We utilized metabolomics data from a subset of 120 subjects recruited as part of a previously described study. All participants met DSM-IV-TR criteria for alcohol dependence. A detailed description of inclusion and exclusion criteria used for this study has been published previously. Recruitment of subjects was from community based residential and outpatient treatment programs affiliated with Mayo Clinic in Rochester, Minnesota and the Mayo Clinic Health System sites in Austin, Minnesota, Albert Lea, Minnesota and La Crosse, Wisconsin as previously described. In total, 443 subjects were assessed for eligibility and acamprosate was initiated. Metabolomics assays were performed on a subset of 120 subjects with complete demographic and clinical data, including alcohol use data at 12-week follow-up, and available serum samples. This group of 120 included 71 subjects that remained completely abstinent during the 12 weeks of acamprosate treatment (“treatment responders”) and 49 subjects that relapse (any alcohol consumption; “non-responders”).

| Performance Index | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Training | Test | Average | SD | Average | SD |
|-------------------|---------|---------|---------|---------|---------|---------|------|---------|----|---------|----|
| True positives    | 44      | 17      | 42      | 19      | 43      | 17      | 48   | 22      | 48 | 23      | 19.6 |
| False positives   | 20      | 8       | 15      | 10      | 16      | 9       | 25   | 16      | 27 | 14      | 11.4 |
| Sensitivity       | 0.936   | 0.708   | 0.893   | 0.792   | 0.915   | 0.708   | 1.000 | 0.957   | 1.000 | 0.949   | 0.049 |
| Specificity       | 0.394   | 0.500   | 0.545   | 0.375   | 0.515   | 0.438   | 0.219 | 0.059   | 0.156 | 0.366   | 0.174 |
| Accuracy          | 0.713   | 0.625   | 0.750   | 0.625   | 0.750   | 0.600   | 0.688 | 0.575   | 0.663 | 0.713   | 0.038 |
| ROC AUC           | 0.832   | 0.659   | 0.845   | 0.578   | 0.802   | 0.570   | 0.756 | 0.724   | 0.771 | 0.801   | 0.038 |

Table 4. Predictive model performance.

Figure 1. Receiver operating characteristic (ROC) curves illustrating the ability of the Lasso penalized selection models to predict acamprosate treatment response in the test set for each of the 5 random splits of the data.
Acamprosate treatment and monitoring. Participants were prescribed one 333 mg tablet three times a day for the first week to determine tolerance of medication. Then, a standard dose of two 333 mg tablet three times a day was prescribed. Subjects were followed monthly for 3 months by in-person interviews (the first and third months) and by phone (the second month) to obtain accurate sobriety, medication compliance (pill counts) and presence of psychiatric symptoms. Response to acamprosate was defined as no alcohol consumption during the 3-month treatment period while non-response was defined as any amount of alcohol consumption during the 3-month treatment period. Response vs. non-response outcome was determined by self-report (TLFB-30) and by measuring levels of GGT to assess accuracy of self-report.

Clinical assessments. Prior to the start of acamprosate treatment (baseline), self-reported history of alcohol consumption was collected by a research coordinator via the 30-day Timeline Follow Back (TLFB-30) method. Baseline anxiety and depressive symptom severity were assessed by the 7-item General Anxiety Disorder Questionnaire [GAD-7; ref. 36] and the 9-item Patient Health Questionnaire [PHQ-9]. Baseline alcohol craving was assessed by the Pennsylvania Alcohol Craving Scale [PACS; ref. 38]. The PACS is a five-item self-report measure with each question scaled from 0 to 6. It quantifies the frequency, intensity, duration of alcohol craving, and the ability to resist drinking over the previous week. Higher scores indicate stronger craving.

Serum collection. At baseline, approximately 20 ml of blood was collected from each subject, which usually occurred between noon and 3 PM. Blood was collected to analyze metabolite levels as well as gamma-glutamyl transpeptidase (GGT) levels as a biological marker of alcohol consumption. Venipuncture was performed using standard techniques. All tubes were labeled with a study identifier, collection date, and time of draw. After collection, samples were electronically accessioned at the Biospecimens Accessioning Processing (BAP) facility at Mayo Clinic. Samples were subsequently spun down for 15 min at 2900 × g at 4 °C and serum was aliquoted into 250 μl samples and stored at −80 °C within 2 h to minimize any possible metabolite degradation. All serum samples were thawed on ice for approximately 2 h before use. Glutamine synthetase activity was measured as described.

Metabolomics using LC-MS/MS. The metabolomics method for analyzing these serum samples using LC-MS/MS has been described previously. Briefly, serum amino acid calibration standards were prepared with a MassTrak Amino Acid Analysis Solution (AAA) kit (Waters Corp, Milford, MA) according to instructions with slight modifications for detection on a mass spectrometer. To measure accurate metabolite concentrations, we first normalized each sample to the internal standard. Serum samples of 10 μl were spiked with an internal standard then derivatized according to MassTrak instructions. The amino acid derivatizing reagent used was 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. Then, concentrations based on the standard curve were determined. A 10-point standard concentration curve was made from the calibration standard solution to calculate amino acid concentrations in serum samples. High resolution separation was done using an Acquity UPLC system and injecting 1 ml of derivatized solution, with a UPLC BEH C18 column (Waters Corp, Milford, MA). Mass detection was completed on a TSQ Ultra Quantum running in ESI positive mode (Thermo Scientific, Waltham, MA).

Statistical analysis. Prior to building multivariable predictive models of acamprosate response, we compared baseline demographic, clinical, and metabolic features between responders (n = 71) and non-responders (n = 49). Unpaired t test were used for continuous variables, while chi-square tests were used for categorical variables.

To investigate the potential utility of multivariable prediction of acamprosate treatment response, subjects were randomized into a training set (2/3 of subjects; n = 80) and a test/validation set (1/3 of subjects; n = 40); this random split was repeated 5 times to allow assessment of variability in the performance of the predictive models. The random split of subjects into test and training datasets was performed in responder/non-responder strata, to ensure a similar proportion of responders across training and test subsets. Sparse logistic regression based on the Lasso approach with four-fold cross-validation optimized for the model deviance was then used for model building, beginning with all variables shown in Tables 1 and 2. The analysis was implemented using the cv.glmnet function in the glmnet R package (https://cran.r-project.org/web/packages/glmnet/glmnet.pdf), with nfolds = 4 and the type = “deviance” option. The models built in the training sets were then used to predict response in the corresponding independent test sets, and the area under the Receiver Operating Characteristic (ROC) curve (AUC), as well as the sensitivity and specificity based on a 0.5 predicted probability cut-off, were calculated to evaluate model performance in the test sets. Mean imputation of five of the metabolic predictors (predictor ([% missing]: phosphoethanolamine [6.7], 1-methylhistidine [17.5], 3-methylhistidine [5.8], 6-aminoisobutyric acid [9.2], cystathionine [5.8]) was conducted prior to analysis to preserve the sample size and create the complete data needed for the Lasso models.

References
1. Grant, B. F. et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 72, 757–766, doi:10.1001/jamapsychiatry.2015.0584 (2015).
2. Harwood, H. J., Fountain, D. & Livernore, G. Economic costs of alcohol abuse and alcoholism. Recent Dev Alcohol 14, 307–330, doi:10.1007/bf012791 (1998).
3. Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S. & Murray, C. J. Selected major risk factors and global and regional burden of disease. Lancet 360, 1347–1360, doi:10.1016/S0140-6736(02)11403-6 (2002).
4. Clapp, P. Current progress in pharmacologic treatment strategies for alcohol dependence. Expert Rev Clin Pharmacol 5, 427–435, doi:10.1586/ercp.12.31 (2012).
5. Heilig, M., Goldman, D., Berrettini, W. & O’Brien, C. P. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12, 670–684, doi:10.1038/nrn3110 (2011).
6. Jonas, D. E. et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311, 1889–1900, doi:10.1001/jama.2014.3628 (2014).
7. Litten, R. Z. et al. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res 39, 579–584, doi:10.1111/acer.12669 (2015).
8. Hou, J. et al. Subgroup Identification in Personalized Treatment of Alcohol Dependence. Alcohol Clin Exp Res 39, 1253–1259, doi:10.1111/acer.12759 (2015).
9. Kranzler, H. R. & McKay, J. R. Personalized treatment of alcohol dependence. Curr Psychiatry Rep 14, 486–493, doi:10.1007/s11920-012-0296-5 (2012).
10. Seneviratne, C. & Johnson, B. A. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. Alcohol Res 37, 15–28 (2015).
11. Hendershot, C. S. Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. Addict Sci Clin Pract 9, 20, doi:10.1186/1940-0609-20 (2014).
12. Anton, R. F. et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65, 135–144, doi:10.1001/archpsyc.65.2.135 (2008).
13. Oroszi, G. et al. OPRM1 AAS40A polymorphism predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33, 383–393, doi:10.1111/j.1530-0277.2008.00846.x (2009).
14. Oslin, D. W. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546–1552, doi:10.1038/npjnp.2003.219 (2003).
15. Oslin, D. W. et al. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA Psychiatry 72, 430–437, doi:10.1001/jamapsychiatry.2014.3033 (2015).
16. Ostman, W. et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 14, 328–337, doi:10.1111/j.1369-1600.2009.00159.x (2009).
17. Kiefer, F. et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 11, 368–374, doi:10.1038/tp.2010.51 (2011).
18. Karpuyk, V. M. et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 4, e462, doi:10.1038/tp.2014.103 (2014).
19. Lee, M. R. et al. Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1. Neurosci Lett 490, 90–95, doi:10.1016/j.neulet.2010.12.033 (2011).
20. Spanagel, R. et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 11, 35–42, doi:10.1038/nm1163 (2005).
21. Kaddurah-Daouk, R. & Weinsilboun, R. M. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 95, 154–167, doi:10.1038/ctp.2013.217 (2014).
22. Bough, K. J. et al. Biomarkers for the development of new medications for cocaine dependence. Neuropsychopharmacology 39, 202–219, doi:10.1038/npp.2013.210 (2014).
23. Kaddurah-Daouk, R. & Weinsilboun, R. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. Clin Pharmacol Ther 98, 71–75, doi:10.1002/cpt.134 (2015).
24. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 1, e2, doi:10.1038/tp.2011.22 (2011).
25. Zhu, H. et al. Pharmacometabolomics response of sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 8, e68283, doi:10.1371/journal.pone.0068283 (2013).
26. Yao, J. K. et al. Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS One 7, e42165, doi:10.1371/journal.pone.0042165 (2012).
27. Condray, R. et al. 3-Hydroxynorepinephrine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 14, 756–767, doi:10.1017/S1461145710001689 (2011).
28. Nam, H. W. et al. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. Transl Psychiatry 5, e621, doi:10.1038/tp.2015.120 (2015).
29. Wood, P. L. Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 39, 24–33, doi:10.1038/npp.2013.167 (2014).
30. Guerguieva, R. et al. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. Eur Neuropsychopharmacol 25, 1586–1599, doi:10.1016/j.eurpharm.2015.06.006 (2015).
31. Dahchour, A. & De Witte, P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res 27, 465–470, doi:10.1097/01.ALC.0000566717.6874.18 (2003).
32. Umhau, J. C. et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67, 1069–1077, doi:10.1001/ archgenpsychiatry.2010.125 (2010).
33. Hinton, D. J. et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropsychopharmacology 62, 2480–2488, doi:10.1016/j.neuropharm.2012.02.022 (2012).
34. Spanagel, R. et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 39, 783–791, doi:10.1038/ npp.2013.264 (2014).
35. Sobell, L. C. et al. Comparison of a quick drinking screen with the timeline followback for individuals with alcohol problems. J Stud Alcohol 64, 858–861, doi:10.15288/jsa.2003.64.858 (2003).
36. Spitzer, R. L., Kroenke, K., Williams, J. B. & Lowe, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166, 1092–1097, doi:10.1001/archinte.166.10.1092 (2006).
37. Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16, 606–613, doi:10.1046/j.1525-1497.2001.0160960.x (2001).
38. Flannery, B. A., Volpicelli, J. R. & Pettinati, H. M. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23, 1289–1295, doi:10.1111/j.1530-0277.1999.tb04349.x (1999).
39. Kingdon, H. S., Hubbard, J. S. & Stadman, E. R. Regulation of glutamine synthetase. XI. The nature and implications of a lag phase in the Escherichia coli glutamine synthetase reaction. Biochemistry 7, 2136–2142, doi:10.1021/bi00846a016 (1968).
40. Lanza, J. R. et al. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 5, e10538, doi:10.1371/journal.pone.010538 (2010).

**Acknowledgements**

We thank Wayne Olson for insightful discussion and De Ann Frederixon for assistance in preparing the manuscript. This work was supported by the Samuel C. Johnson for Genomics of Addiction Program at Mayo Clinic, the Ulm Foundation, David Lehr Research Award from American Society for Pharmacology and Experimental Therapeutics, Mayo–Karolinska Institute (KI) Research Award and National Institute on Alcohol Abuse and Alcoholism (AA018779, AA017830).
Author Contributions
D.J.H., M.S.V. and D.S.C. wrote the article; D.J.H., M.S.V. and D.S.C. designed the research; D.J.H., M.S.V. M.J.H., A.M.C.H., V.M.K. and D.S.C. performed the research; D.J.H., M.S.V. M.J.H., J.R.G., J.M.B. and D.S.C. analyzed the data. All authors critically reviewed contents and approved the final version of the manuscript for publication.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017